CARA Therapeutics, Inc. (CARA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Bionano Genomics, Inc.

Cue Biopharma, Inc.

CARA Therapeutics, Inc.

Immunome, Inc.

NGM Biopharmaceuticals, Inc.

Aadi Bioscience, Inc.

Armata Pharmaceuticals, Inc.

IO Biotech, Inc.

Cyteir Therapeutics, Inc.

Anixa Biosciences, Inc.

Omega Therapeutics, Inc.

Why is CARA Therapeutics, Inc. ?

Poor Management Efficiency with a low ROE of 1.22%

The company has been able to generate a Return on Equity (avg) of 1.22% signifying low profitability per unit of shareholders funds

Poor long term growth as Operating profit has grown by an annual rate 11.71% of over the last 5 years

Flat results in Jun 25

NET SALES(9M) At USD 4.02 MM has Grown at -21.7%
INTEREST(HY) At USD 2.87 MM has Grown at 44.65%
CASH AND EQV(HY) Lowest at USD 75.21 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 9108.32%, its profits have risen by 68.7%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is CARA Therapeutics, Inc. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

CARA Therapeutics, Inc.

-58.16%

0.09

263.34%

S&P 500

13.22%

0.96

19.87%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-22.82%

EBIT Growth (5y)

12.53%

EBIT to Interest (avg)

-43.80

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.44

Sales to Capital Employed (avg)

0.23

Tax Ratio

0.88%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

56.63%

ROCE (avg)

3.91%

ROE (avg)

1.22%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-33.03

EV to EBIT

-9.00

EV to EBITDA

-9.05

EV to Capital Employed

78.80

EV to Sales

36.75

PEG Ratio

Dividend Yield

ROCE (Latest)

-875.16%

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -31.57 MM

NET PROFIT(HY)

Higher at USD -13.49 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

EPS(Q)

Highest at USD -1

-16What is not working for the Company

NET SALES(9M)

At USD 4.02 MM has Grown at -21.7%

INTEREST(HY)

At USD 2.87 MM has Grown at 44.65%

CASH AND EQV(HY)

Lowest at USD 75.21 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 0%

OPERATING PROFIT(Q)

Lowest at USD -8.87 MM

PRE-TAX PROFIT(Q)

Lowest at USD -8.59 MM

NET PROFIT(Q)

Lowest at USD -8.59 MM

Here's what is working for CARA Therapeutics, Inc.

Operating Cash Flow

Highest at USD -31.57 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

EPS

Highest at USD -1

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for CARA Therapeutics, Inc.

Net Sales

At USD 4.02 MM has Grown at -21.7%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Interest

At USD 2.87 MM has Grown at 44.65%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Profit

Lowest at USD -8.87 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -8.59 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit

At USD -8.59 MM has Fallen at -24.52%

over average net sales of the previous four periods of USD -6.89 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -8.59 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Net Profit

At USD -8.59 MM has Fallen at -26.35%

over average net sales of the previous four periods of USD -6.79 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 75.21 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 0%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio